Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study

Publication date: May 2018
Source:European Journal of Cancer, Volume 94
Author(s): J.L. Ethier, A. Ocaña, A. Rodríguez Lescure, A. Ruíz, E. Alba, L. Calvo, M. Ruíz-Borrego, A. Santaballa, C.A. Rodríguez, C. Crespo, M. Ramos, J. Gracia Marco, A. Lluch, I. Álvarez, M. Casas, M. Sánchez-Aragó, E. Carrasco, R. Caballero, E. Amir, M. Martin
BackgroundRetrospective data suggest better outcomes for patients with double hormonal receptor (oestrogen [ER] and progesterone receptor [PgR])–positive (dHR+) early breast cancer, compared with single hormonal receptor–positive, sHR+, (ER+/PgR– or ER–/PgR+) disease. Here, we evaluate the classification according to intrinsic subtypes and clinical outcomes of sHR+ versus dHR+ in HER2-negative breast cancer patients enrolled in GEICAM/9906 study (NCT00129922).MethodsArchival tumours were retrieved retrospectively for the analysis of ER, PgR and HER2 status and classified into intrinsic subtypes using the PAM50 gene expression assay. Disease-free survival (DFS) and overall survival (OS) were explored using a Cox proportional hazard analysis.ResultsData on intrinsic subtypes were available in 571 (50%) patients with ER+ and/or PR+, and HER2-negative primary tumours. The incidence of luminal A and luminal B subtypes were 52%/36% in dHR+ tumours (ER+/PgR+), and 15%/58% in ER+/PgR–tumours. ER–/PgR+ tumours were mainly luminal A (52%). Compared with ER+/PgR+ patients, DFS was similar in ER–/PgR+ (hazard ratio [HR] 1.15, 95% confidence interval [CI] 0.57–2.34, p = 0.70) but worse in ER+/PgR– patients (HR 1.60, 95% CI 1.12–2.28, p < 0.01). Similar results were observed for OS (HR 1.50, p = 0.30 and HR 1.86, p < 0.01, respectively).ConclusionsThe ER+/PgR– group is characterised by higher proliferation and worse outcomes. In spite of the ER–/PgR+ subgroup resembles ER+/PgR+ disease in terms of molecular subtypes and outcomes, the small number of patients in this subgroup prevents from drawing any conclusions.Trial registrationEudraCT: 2005-003108-12 (retrospectively registered 28/06/2005).Clinicaltrials.gov IdentifierNCT00129922 (retrospectively registered 10/08/2005).



from Cancer via ola Kala on Inoreader http://ift.tt/2pvkraO
via IFTTT